GKSL · NSE
Gujarat Kidney And Super Speciality Limited
₹181.25
+1.93% (+₹3.43)
Prev. close
₹177.82
Volume
2,73,151
Delivery %
35.0%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Gujarat Kidney And Super Speciality Limited
Gujarat Kidney and Super Speciality Limited operates multi-specialty and super-specialty hospitals in India. It provides treatment for Oncology, Neurology, Gastroenterology, Urology, Nephrology, and Physiotherapy. It also offers Renal Surgery, Vascular Surgery, Gynecology and obstetrics, Robotic Surgery, Bariatric Surgery, Laparoscopic Surgery, Endocrine Surgery, Neurosurgery, and Joint Replacement services. Its facilities include intensive care unit, rooms, patient counselling, operation theatres, and dialysis center. Gujarat Kidney And Super Speciality Limited was founded in 2014 and is headquartered in Vadodara, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Ms. Bhavikaben Mitesh Patel
Headquarters
Vadodara
Employees
194
Exchange
View on NSE ↗Key stats
Market cap
₹1,429.03 Cr
P/E ratio (TTM)
90.2
EPS (TTM)
₹2.01
Shares float
1.32 Cr
EPS · quarter ended Jun 2026
₹0.66
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
Other assets floored at zero for years where fixed and current assets exceeded reported total assets.
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹85.79 Cr | ₹103.44 Cr | ₹36.78 Cr | ₹60.60 Cr | |
| EBITDA | ₹17.93 Cr | ₹22.03 Cr | ₹16.69 Cr | ₹27.81 Cr |
| ₹6.64 Cr | ₹9.68 Cr | ₹9.41 Cr | ₹15.50 Cr | |
| Diluted EPS | ₹0.84 | ₹1.23 | ₹1.19 | ₹2.49 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹4.00 Cr | ₹21.00 Cr | ₹55.00 Cr | ₹298.00 Cr | |
| ₹23.20 Cr | ₹27.34 Cr | ₹8.31 Cr | ₹29.11 Cr | |
| Stockholders' equity | ₹20.00 L | ₹11.20 Cr | ₹26.00 Cr | ₹253.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹1,000 | ₹1.21 Cr | ₹13.61 Cr | ₹-3.86 Cr | |
| Investing cash flow | ₹0 | ₹22.33 L | ₹-18.14 Cr | ₹-213.85 Cr |
| ₹0 | ₹0 | ₹6.00 Cr | ₹228.00 Cr | |
| Capital expenditure | — | — | ₹-18.25 Cr | ₹-94.42 Cr |
| End cash position | ₹35,000 | ₹97.03 L | ₹2.60 Cr | ₹13.28 Cr |
Dividends paid, Capital expenditure have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 25–Jun 26(4Q) |
|---|---|
| Promoter | 71.45% |
| Public | 28.55% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Gujarat Kidney And Super Speciality Limited | ₹1,401.98 Cr | ₹181.25 | 88.0 | 5.55 | 6.1% | 0.12 | +64.8% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
4 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.